Results 131 to 140 of about 6,598 (226)

The long-term effect of elexacaftor/tezacaftor/ivacaftor on cardiorespiratory fitness in adolescent patients with cystic fibrosis: a pilot observational study

BMC Pulmonary Medicine
Background Physical activity is a crucial demand on cystic fibrosis treatment management. The highest value of oxygen uptake (VO2peak) is an appropriate tool to evaluate the physical activity in these patients.
Nela Stastna, Lenka Hrabovska, Pavel Homolka, Lukas Homola, Michal Svoboda, Kristian Brat, Libor Fila   +6 more
doaj   +1 more source

Clinical and radiological improvement of cavitary Mycobacteroides abscessus disease in cystic fibrosis following initiation of elexacaftor/tezacaftor/ivacaftor [PDF]

Roderick Gavey, J D Nolan, Vanessa Moore, David W. Reid, James S. Brown   +4 more
openalex   +1 more source

326 Modulator response of rare CFTR missense variants not approved for elexacaftor-tezacaftor-ivacaftor

, 2023
Deepak Joshi, András Rab, Eric J. Sorscher, Jeong S. Hong   +3 more
openalex   +1 more source

Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis [PDF]

, 2023
Valentina Fainardi, Kaltra Skenderaj, Andrea Ciuni, Gianluca Milanese, Michela Deolmi, Francesco Longo, Cinzia Spaggiari, Nicola Sverzellati, Susanna Esposito, Giovanna Pisi   +9 more
openalex   +1 more source

Deciphering pediatric respiratory diseases using single-cell RNA sequencing [PDF]

The respiratory system comprises specialized cell types that maintain homeostasis and facilitate air conductance and gas exchange. Disease states often involve dysregulation of this balance, leading to changes in cell composition and molecular profiles ...
Loske, Jennifer
core   +1 more source

<p>Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis</p>

, 2019
Dejene Shiferaw, Shoaib Faruqi
openalex   +2 more sources

EPS5.02 Faecal microbiota changes in patients with cystic fibrosis with 6 months of elexacaftor/tezacaftor/ivacaftor: preliminary findings from the PROMISE study [PDF]

, 2023
J. Duong, Charles E. Pope, Hillary S. Hayden, C. Miller, Daniel Raftery, Stephen J. Salipante, J. Pittman, Félix Ratjen, Margaret Rosenfeld, Steven M. Rowe, George M. Solomon, David P. Nichols, Lucas R. Hoffman   +12 more
openalex   +1 more source

581 Glycemia and insulin secretion before and 2 years after elexacaftor-tezacaftor-ivacaftor initiation [PDF]

, 2023
Christine L. Chan, Matt Shirley, R. Walega, Steven M. Rowe, D. Nichols, D. Stefanovski, Michael S. Stalvey, G. Solomon, Andrea Kelly   +8 more
openalex   +1 more source

Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis

Therapeutics and Clinical Risk Management, 2019
Dejene Shiferaw,* Shoaib Faruqi*Department of Respiratory Medicine, Hull University Teaching Hospitals NHS Trust, Cottingham HU16 5JQ, UK *These authors contributed equally to this workCorrespondence: Shoaib FaruqiDepartment of Respiratory Medicine ...
Shiferaw D, Faruqi S
doaj  

Multidimensional Impacts of Elexacaftor/Tezacaftor/Ivacaftor: Comparisons of Physical and Mental Health Providers' Observations in Cystic Fibrosis in Europe and the United States [PDF]

Sonia Graziano, E. Landau, Horst Mitmansgrubert, Marieke Verkleij, Anna M. Georgiopoulos, U. Borawska-Kowalczyk, Beth A. Smith, Christina J. Bathgate, Alexandra L. Quittner   +8 more
openalex   +1 more source